How GLP-1 Weight Loss Drugs Affect Bone Health in People With Obesity: A Review
GLP-1 receptor agonists used for weight loss appear to cause modest reductions in bone mineral density and increase bone turnover, similar to what happens with calorie restriction alone.
Quick Facts
What This Study Found
In rodent models, liraglutide positively influenced bone material properties despite weight loss, but the most favorable effects on bone mineral density and microarchitecture occurred at doses much higher than those approved for human obesity treatment.
In humans with obesity, preliminary findings indicate GLP-1 receptor agonists cause modest bone mineral density reduction and enhance bone remodeling that favors resorption — a pattern similar to the effects seen with calorie restriction producing 7–10% weight loss. Significant weight reduction through calorie restriction or bariatric surgery consistently results in high-turnover bone loss.
Key Numbers
How They Did This
This was a comprehensive literature review of preclinical studies and human data published in English from January 2013 to December 2024. The authors searched for studies examining the effects of GLP-1 receptor agonists on bone health, and also summarized data on bone outcomes from calorie restriction and bariatric surgery for context.
Why This Research Matters
With millions of people now using GLP-1 drugs for weight loss, understanding their bone health implications is critical — especially since significant weight loss from any cause is known to reduce bone density. This review helps clarify whether bone changes seen with these drugs are a direct drug effect or simply a consequence of losing weight.
The Bigger Picture
As GLP-1 receptor agonists expand from diabetes treatment into mainstream weight management, and as newer dual- and triple-receptor agonists (GLP-1/GIP/glucagon) emerge, understanding skeletal side effects becomes increasingly important. This is especially relevant for postmenopausal women and older adults who are already at elevated fracture risk.
What This Study Doesn't Tell Us
Current evidence on GLP-1 RA effects on bone health in humans with obesity is limited. Most robust bone data comes from animal models using doses higher than those used clinically. The review did not include fracture outcome data, which would be the most clinically meaningful endpoint. The bone effects may be confounded by weight loss itself rather than representing a direct drug effect.
Questions This Raises
- ?Do GLP-1 receptor agonists increase actual fracture risk in people using them for weight loss, or are the bone density changes clinically insignificant?
- ?How do newer dual- and triple-receptor agonists (GLP-1/GIP/glucagon) compare to pure GLP-1 agonists in their effects on bone?
- ?Should bone density monitoring be recommended for patients on long-term GLP-1 RA therapy for weight management?
Trust & Context
- Key Stat:
- 7–10% weight loss The threshold at which weight reduction — whether from calorie restriction, surgery, or medication — consistently leads to high-turnover bone loss
- Evidence Grade:
- This is a narrative review summarizing preclinical and clinical evidence. While it synthesizes a broad range of studies, it is not a systematic review or meta-analysis, and the human data on bone outcomes with GLP-1 RAs remains limited.
- Study Age:
- Published in 2025, this review covers literature through December 2024 and represents the most current synthesis of GLP-1 RA bone health data available.
- Original Title:
- Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.
- Published In:
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 36(11), 2115-2126 (2025)
- Authors:
- Karam, Léa, Mabilleau, Guillaume, Paccou, Julien(3)
- Database ID:
- RPEP-11727
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 weight loss drugs weaken your bones?
Current evidence suggests GLP-1 drugs cause a modest reduction in bone mineral density and increase bone turnover, but these effects appear similar to what happens with any significant weight loss (around 7–10% of body weight). It is not yet clear whether this translates to an increased risk of fractures. More research specifically tracking fracture outcomes is needed.
Should I worry about bone health if I'm taking semaglutide or liraglutide for weight loss?
While the bone density changes observed so far are modest, it may be worth discussing with your doctor — especially if you have other risk factors for osteoporosis such as older age, menopause, low calcium intake, or a history of fractures. Exercise, particularly weight-bearing activity, during weight loss can help preserve bone density.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11727APA
Karam, Léa; Mabilleau, Guillaume; Paccou, Julien. (2025). Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 36(11), 2115-2126. https://doi.org/10.1007/s00198-025-07664-1
MLA
Karam, Léa, et al. "Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.." Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. https://doi.org/10.1007/s00198-025-07664-1
RethinkPeptides
RethinkPeptides Research Database. "Effects of Glucagon-Like Peptide-1 receptor agonists on bone..." RPEP-11727. Retrieved from https://rethinkpeptides.com/research/karam-2025-effects-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.